Breast cancer lumpectomy: fewer reoperations with neoadjuvant vs adjuvant chemotherapy

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Receipt of neoadjuvant chemotherapy vs receipt of postoperative chemotherapy is associated with fewer reoperations after lumpectomy for breast cancer.

Why this matters

 

 

  • Reoperation is common, with more than 1 in 5 patients treated with lumpectomy undergoing reoperation for perceived residual disease.

Study design

 

 

  • 71,627 patients with stages I-III breast cancer in the National Cancer Database (NCDB) were evaluated for type of chemotherapy and reoperation rates (RORs) using multivariable logistic regression modeling.
  • Funding: Gundersen Medical Foundation, Norma J. Vinger Center for Breast Care, University of Wiscosin La Crosse.

Key results

 

 

  • The RORs were 11.4% for those who received neoadjuvant chemotherapy vs 20.3% for those who received postoperative chemotherapy (unadjusted OR=0.53; P<.001).
  • The ORs for reoperations for patients with stage 1 cancer was 0.65 (P<.001), with stage II cancer was 0.50 (P<.001), and with stage III cancer was 0.27 (P<.001).

Limitation

 

 

  • There was some missing data for ROR because the NCDB does not have a field for ROR.